<DOC>
	<DOCNO>NCT00731263</DOCNO>
	<brief_summary>The purpose study assess safety , tolerability pharmacokinetics AZD8055 determine maximum tolerate dose take phase II trial .</brief_summary>
	<brief_title>A Study Tor Kinase Inhibitor Advanced Tumors</brief_title>
	<detailed_description />
	<criteria>Histological cytological confirmation advance solid malignant tumour ( lymphoma Part A ) Cancer refractory standard therapy standard therapy exists , patient measurable nonmeasurable disease ( accord RECIST criterion ) recruit Part A Evidence postmenopausal status negative urine/serum pregnancy test premenopausal female patient Patients severe laboratory abnormality haematology , liver renal function . Also treatment haemopoietic growth factor allow within two week first dose study drug . Patients abnormal fast glucose , type I II Diabetes uncontrolled blood fat cholesterol Patients history neurological disease , peripheral central neuropathy , brain metastasis family history myopathy exclude Patients severe cardiac condition ischemia , impair ventricular function arrhythmia , evidence severe uncontrolled systemic current unstable uncompensated respiratory cardiac condition</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>Cancer</keyword>
	<keyword>Advance solid tumour</keyword>
	<keyword>Dose Escalation</keyword>
	<keyword>Preliminary efficacy</keyword>
	<keyword>AZD8055</keyword>
	<keyword>Tor kinase inhibitor</keyword>
	<keyword>Oral administration</keyword>
</DOC>